Company / Operating Margin
Avalo Therapeutics, Inc. Operating Margin History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-123601.7%
FY2025
5-year range
-123601.7% / -207.4%
FY2021-FY2025
Trend
-695.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin changed -696% YoY in FY2025, a notable deviation from the 8-year average annual change of -455%.
Based on SEC 10-K filings.
-123601.7% in FY2025 with a 5-year CAGR of -122514.3%.
Declined from -1421.6% to -123601.7% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -123394.3pp
- 5-Year Change
- -122514.3pp
- 10-Year Change
- -
Key checks
Key Insights
- Avalo Therapeutics, Inc.'s operating margin has declined for 3 consecutive years.
- In FY2025, operating margin decreased 695.6% year-over-year.
- Peak operating margin was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -123601.7% | -695.6% |
| FY2024 | -15535.6% | -992.8% |
| FY2023 | -1421.6% | -585.4% |
| FY2022 | -207.4% | +86.4% |
| FY2021 | -1521.6% | -39.9% |
| FY2020 | -1087.4% | -354.9% |
| FY2019 | -239.1% | +52.5% |
| FY2018 | -503.4% | -1107.9% |
| FY2017 | 49.9% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026